National consensus statement by the Austrian Societies for Rheumatology, Pulmonology, Infectiology, Dermatology and Gastroenterology regarding the management of latent tuberculosis and the associated utilization of biologic and targeted synthetic disease modifying antirheumatic drugs (DMARDs)
Rath E, Bonelli M, Duftner C, Gruber J, Mandl P, Moazedi-Furst F, Pieringer H, Puchner R, et al. (17 authors)
Wiener klinische Wochenschrift · 2022-08
Abstract
This publication provides a thorough analysis of the most relevant topics concerning the management of latent tuberculosis when using biologic and targeted synthetic Disease Modifying Antirheumatic Drugs (DMARDs) by a multidisciplinary, select committee of Austrian physicians. The committee includes members of the Austrian Societies for Rheumatology and Rehabilitation, Pulmonology, Infectiology, Dermatology and Gastroenterology. Consensus was reached on issues regarding screening and treatment of latent tuberculosis and includes separate recommendations for each biologic and targeted synthetic DMARD.
MeSH terms
- Humans
- Arthritis, Rheumatoid
- Antirheumatic Agents
- Biological Products
- Dermatology
- Gastroenterology
- Rheumatology
- Austria
- Pulmonary Medicine
- Latent Tuberculosis